Enterprise value of leading pure players in non-oncology rare disease therapeutics worldwide as of 2017 (in million U.S. dollars)*

Enterprise value of top companies in non-oncology rare disease therapeutics 2017 This statistic shows the enterprise value of leading pure players in non-oncology rare disease therapeutics worldwide as of 2017. In 2017, the value of Biogen which manufactures especially multiple sclerosis therapeutics stood at nearly 70 billion U.S. dollars.
Show more
Loading statistic...
Expand statistic
Value in million U.S. dollars
Biogen69,812
Shire (+predecessors)67,777
Vertex Pharma37,428
Genzyme36,070
Alexion33,114
BioMarin16,261
Jazz Pharma10,141
Bioverativ6,086
Ionis Pharma6,053
bluebird bio5,320
United Therapeutics4,225
Swedish Orphan Biovitrum4,073
Horizon Pharma3,409
Spark Therapeutics3,044
AveXis, Inc.2,671
Amicus Therapeutics2,416
Corcept Therapeutics2,127
Prothena Corporation2,060
Ultragenyx1,970
Intercept Pharma1,624
Value in million U.S. dollars
Biogen69,812
Shire (+predecessors)67,777
Vertex Pharma37,428
Genzyme36,070
Alexion33,114
BioMarin16,261
Jazz Pharma10,141
Bioverativ6,086
Ionis Pharma6,053
bluebird bio5,320
United Therapeutics4,225
Swedish Orphan Biovitrum4,073
Horizon Pharma3,409
Spark Therapeutics3,044
AveXis, Inc.2,671
Amicus Therapeutics2,416
Corcept Therapeutics2,127
Prothena Corporation2,060
Ultragenyx1,970
Intercept Pharma1,624

© Statista 2018

Download Settings Share
Chart type
Datalabels
Share on Social Media
HTML code to embed chart as PNG (FAQ)
Download started
Please be patient - this may take a moment
Description Source More information
This statistic shows the enterprise value of leading pure players in non-oncology rare disease therapeutics worldwide as of 2017. In 2017, the value of Biogen which manufactures especially multiple sclerosis therapeutics stood at nearly 70 billion U.S. dollars.
Show more
Release date
2017
Region
Worldwide
Survey time period
as of October 2017
Special properties
non-oncology rare disease therapeutics
Method of interview
Online survey
Supplementary notes
* All values are in current U.S. dollars.

Statista Accounts: Access All Statistics. Starting from $588 / Year

Statistics on "Pharmaceutical trends in Europe"

  • Overview
The most important statistics
  • European Pharmaceutical companies
The most important statistics
  • Self-medication market
The most important statistics
  • Clinical Trials
The most important statistics

Statista for Your Company: The Research and Analysis Tool

  • Product Film
  • Statistics
  • Downloads

Our Premium Statistics - facts for your business

Currently, Statista provides more than 1 million statistics.
93 percent (all Premium content) are exclusively accessible via our professional accounts.

Unlimited access

As a Statista Premium customer, you receive unlimited access to all statistics at all times. Including downloads of data in the most common formats (XLS, PDF & PNG). Create relevant and significant statistics in no time.

You are in good company

Further Content: Statistics, Studies, and Topic Pages

Our Business Solutions: Save Time and Money

only

$588*

per year
Your advantages
  • Full access to all our statistics
  • Download as XLS, PDF & PNG
  • Relevant data: complete source information
All functions of our platform illustrated face-to-face
  • Learn how Statista supports your company
  • Extensive tour across the whole portal
  • Personal guidance by our support team
The knowledge database for your company
  • All functions of the Premium Account
  • Access to dossiers, forecasts and studies
  • Access to our international database
  • Publishing rights and other exclusive functions

Statistics on the topic

Topics

About Statista

Learn more about how Statista can support your business.

Request webinar